Naproxcinod

Naproxcinod (Nitronaproxen) is the first in class of cyclooxygenase (COX) -inhibiting nitric oxide donators (CINODs) . Naproxcinod shows analgesic and anti-inflammatory effects, it can be used for the research of osteoarthritis and inflammation[1][2][3].

Product Specifications

CAS Number

[163133-43-5]

Product Name Alternative

AZD 3582; HCT 3012; Nitronaproxen

UNSPSC

12352005

Hazard Statement

H302-H373-H400-H410

Target

COX

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/naproxcinod.html

Solubility

10 mM in DMSO

Smiles

C[C@@H](C1=CC=C2C=C(OC)C=CC2=C1)C(OCCCCO[N+]([O-])=O)=O

Molecular Formula

C18H21NO6

Molecular Weight

347.36

Precautions

P260-P264-P270-P273-P330-P391-P501

References & Citations

[1]Berndt G, et al. A common pathway of nitric oxide release from AZD3582 and glyceryl trinitrate. Eur J Pharm Sci. 2004 Feb;21 (2-3) :331-5.|[2]Berndt G, et al. AZD3582 increases heme oxygenase-1 expression and antioxidant activity in vascular endothelial and gastric mucosal cells. Eur J Pharm Sci. 2005 Jun;25 (2-3) :229-35. |[3]Uaesoontrachoon K, et al. Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy. Hum Mol Genet. 2014 Jun 15;23 (12) :3239-49.